Dr. Guna Muppuri Chairman of the Board For Indies Pharma Jamaica Limited has released the following report for the Six-month period ended April 30, 2023.
For the Six-month period ended April 30, 2023, Indies Pharma Jamaica Limited earned gross revenues of J$487 million and J$463 million in the prior comparable quarter of 2022, representing a 5% or J$24.3M increase.
Gross profits for the Six-month period increased to J$339 million, a 1% increase or J$3.6 million when compared to the similar period in 2022.
Cost of Goods Sold (COS) came in at J$20.7M or 16% higher than prior year and was mainly responsible for this relatively flat showing. Marketing samples given out in the trade have been identified as a major contributor (approx. J$12 million) to this increase. The ROI on this “spend” is expected to be realized over the course of the financial year.
Administrative expenses increased by 14% or J$26 million year over year. This was largely driven by increases in Drug permit costs, Admin Salaries, Wages, usual yearly Royalty expense and Administration.
This resulted in the profit from operations declining by J$22.2 million or 14% compared to similar period in 2022. These were largely responsible for Net Profits for the six-month period being J$26.4 million or 23% lower than the corresponding period of 2022.
• Total assets at the end of the six-month period stood at J$2.245 billion, marginally reduced by 0.4% or J$9.5 million from J$2.255 billion in the comparative period last year.
• Shareholders’ equity has increased by 2.2% or J$23.2 million this year to J$1.1billion compared to J$1.07 billion in the prior period 2022 and total liabilities decreased by 3% from J$1.18 billion to J$1.15 billion.
• Earnings per share (EPS) for the six-month period 2023 fell by 22% to J$0.07/share from $0.09/share when compared to the corresponding period last year.
Results For The Second Quarter Ended April 2023
For the second quarter ended April 2023 revenues decreased by $19.1 million (9%) to that of the corresponding period 2022. This is attributed to the late arrival of inventory in April 2023 precluding the timely billing of sales for this quarter impacting the revenues. However, this is expected to be realized in subsequent month / quarter.
In addition to the above, increased market sampling costs leading to a sudden surge in demand for the key product line, leading to early out of stock situation of the “cash cow” products and therefore the delays in the replenishment lead times. This is a new learning opportunity the company has encountered for the first time. This has led the company to reengineer new strategies to deal with this unprecedented interim shortfall and capitalize as the future benefit.
Gross profits for the quarter fell by $14.7 million or 8% to $163.8 million when compared to the previous quarter of 2022. The decrease in Sales revenues combined with the increase in Cost of Sales (COS) are the contributing factors to this decline in Gross Profits.
Administration and Other Expenses increased to $118.7 million for the current quarter in comparison to $99 million in the corresponding quarter in the previous year; this represents an increase of 20%. Contributing factors are due to increases in servicing cost for fleet vehicles and contractual agreement for Bioprist royalty.
Net Profit for the three-month period also declined, by 56% or J$35.8 million to J$28.4 million from J$64.2 million in the corresponding three-month period in 2022. As indicated above, this transient reduction in the profits during this quarter is mainly because of:
• The late arrival of inventory in April 2023 precluded the timely billing of sales for this quarter impacting the revenues which shall be realized in the subsequent month / quarter.
• “Adoption of IFRS 16” leases and reclassification of maintenance expenses.
• Increase in the cost of sales due to writing off the expired goods and increase in the marketing samples budget to capitalize for the future benefit.
Earnings per share (EPS) for the second quarter (for the three-month period) 2023 fell by 60% to J$0.02/share from $0.05/share when compared to the same period last year.
The company has not taken its focus off from managing and implementing strategies to resolutely manage and control expenses and the cost of sales.
The Company continues to remain healthy and fledgling towards the US market despite a few interim minor challenges mentioned above.
The $805 million bond attained in 2020 towards “Growth Capital” continues to remain on the books as we continue to grow the company through the organic development and approval of two new drugs at the USFDA for the United States Market. It should be noted that we successfully submitted our very first ANDA – Abbreviated New Drug Application (generic drug dossier) on the 25 January 2023 at the USFDA. The same was accepted by the USFDA without any rejections or queries on the 24th of February 2023 with a gold date of approval as November 2023.
The product filed at the USFDA is a patent challenge under the paragraph IV filing which has now been accepted and gone unopposed by the innovator drug company on the United States market. This is an incredible development that is destined to reap the benefits for the company from the US market in the immediate short future.
We continue to constantly deliver and maintain a consistent upward trend in our performance and positive outlook. Our hallmark and clarion call of “Caring for the Nation’s Health” and looking out for the welfare of our end users could not have been possible without the dedication of our loyal customers and hardworking employees.
For More Information CLICK THIS LINK